Seres Therapeutics CFO Marella Thorell to Resign Effective November 15, 2026
MCRB is trading near its 52-week low of $1.98 (0.0% above the low).
Summary
Seres Therapeutics' CFO Marella Thorell resigned effective November 15, 2026, and will advise during the transition. No replacement has been named at a company facing a going-concern warning and cash runway only into Q1 2027.
Key Events · Executive and Board Changes · MCRB
-
CFO Resigns Effective November 15
Executive Vice President and Chief Financial Officer Marella Thorell resigned on October 22, 2026, effective November 15, 2026.
-
Advisory Transition, No Successor Named
Thorell is expected to provide advisory services after the effective date on terms still to be agreed; the filing names no replacement CFO.
-
Timing Adds to Cash Concerns
The departure comes as the company carries a going-concern warning and cash runway only into Q1 2027, per the last 10-Q filed 2026-08-05.
Analysis · MCRB · Life Sciences
Losing the person who manages the balance sheet and any future raise is a real risk at a company already burning cash, carrying a going-concern warning, and with runway only into Q1 2027. She stays on in an advisory role to smooth the handoff, but no successor has been named, leaving a gap in financial leadership at the worst possible time.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MCRB was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.7M. The 52-week trading range was $1.98 to $29.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.